Children diagnosed with attention deficit hyperactivity disorder (ADHD) may now have an alternative therapy option available to them and their families. Neurosigma, a California-based business specializing in bioelectronic devices, has just received FDA approval to market the first ever medical device for treatment of the disorder through low level electrical stimulation of specific nerve branches in the body...
Sorry, you need to subscribe to read this article.
If you would like to access this article, please subscribe below.
Premium subscribers receive complete access to our site content which includes market research and insights as well as coverage of the most important news, issues and events related to the healthcare technology industry.